“Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s251. doi:10.25251/skin.7.supp.251.